This review aims to present the most recent results from clinical trials of targeted cancer drugs that led to the Food and Drug Administration approval in 2021 and reflect the changing treatment landscape of solid malignancies.
Data Sources
Novel approvals and supplemental approvals in 2021 were retrieved from the official web page of the Food and Drug Administration (Drugs@FDA). This review did not include approvals for generics, biosimilars, imaging, and diagnostics agents.
Data Summary
This review included 10 novel drugs approved for 11 indications and 10 already-approved drugs approved for 21 indications by the Food and Drug Administration in 2021. Novel approvals mainly were related to treating an orphan disease. In addition, one-third of the supplemental approvals were given for neoadjuvant or adjuvant treatment, while the number of indications for each tumor site was as follows: gastrointestinal (7), genitourinary (5), skin (3), lung (2), breast (2), thyroid (1), and cervix (1).
Conclusions
Targeted cancer treatments are gaining more importance than ever in treating malignant diseases. As the approval of targeted cancer drugs provides a possibility for patients and this trend is expected to continue in the future, it remains vital for healthcare providers to stay up-to-date with newer therapeutic options.
SunJWeiQZhouY, et al.A systematic analysis of FDA-approved anticancer drugs. BMC Syst Biol2017; 3:11: 87.
2.
WangSYangQDengL, et al.An overview of cancer drugs approved through expedited approval programs and orphan medicine designation globally between 2011 and 2020. Drug Discov Today2021; S1359–6446: 00572–00579.
3.
BeaverJAHowieLJPelosofL, et al.A 25-year experience of US food and drug administration accelerated approval of malignant hematology and oncology drugs and biologics. JAMA Oncol2018; 4: 849–856.
4.
JohnsonJRNingY-MFarrellA, et al.Accelerated approval of oncology products: the food and drug administration experience. J Natl Cancer Inst2011; 103: 636–644.
5.
U.S. Food and Drug Administration, Center For Drug Evaluation and Research. Advancing health through innovation: new drug therapy approvals 2021, https://www.fda.gov/media/155227/download (2022, accessed 24 February 2022).
6.
U.S. Food and Drug Administration. In vitro companion diagnostic devices: Guidance for industry and food and drug administration staff, https://www.fda.gov/media/81309/download (2014, accessed 27 May 2022).
7.
ParkKHauraEBLeighlNB, et al.Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study. J Clin Oncol2021; 39: 3391–3402.
8.
JonaschEDonskovFIliopoulosO, et al.Belzutifan for renal cell carcinoma in von Hippel–Lindau disease. N Engl J Med2021; 385: 2036–2046.
9.
OakninAGilbertLTinkerAV, et al.Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study. J Immunother Cancer2022; 10: e003777.
10.
AndreTBertonDCuriglianoG, et al.Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: results from GARNET study.J Clin Oncol2021; 39: 9.
11.
JavleMRoychowdhurySKelleyRK, et al.Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol2021; 6: 803–815.
12.
ZhouCRamalingamSLiB, et al.Mobocertinib in NSCLC with EGFR exon 20 insertions: results from EXCLAIM and pooled platinum-pretreated patient populations. J Thorac Oncol2021; 16: S108.
13.
SkoulidisFLiBTDyGK, et al.Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med2021; 384: 2371–2381.
14.
PaikPKFelipEVeillonR, et al.Tepotinib in non–small-cell lung cancer with MET exon 14 skipping mutations. N Engl J Med2020; 383: 931–943.
15.
ColemanRLLorussoDGennigensC, et al.Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol2021; 22: 609–619.
16.
RiniBIPalSKEscudierBJ, et al.Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. Lancet Oncol2020; 21: 95–104.
17.
WeissJMCsosziTMaglakelidzeM, et al.Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase ib/randomized phase II trial. Ann Oncol2019; 30: 1613–1621.
18.
JohnstonSRDHarbeckNHeggR, et al.Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR + , HER2 − , node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol2020; 38: 3987–3998.
19.
FelipEAltorkiNZhouC, et al.Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet2021; 398: 1344–1357.
20.
BroseMSRobinsonBShermanSI, et al.Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol2021; 22: 1126–1138.
21.
StratigosAJSekulicAPerisK, et al.Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol2021; 22: 848–857.
SezerAKilickapSGümüşM, et al.Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet2021; 397: 592–604.
24.
TaberneroJGrotheyAVan CutsemE, et al.Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study. J Clin Oncol2021; 39: 273–284.
25.
ZhuAXMacarullaTJavleMM, et al.Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial. JAMA Oncol2021; 7: 1669–1677.
26.
KellyRJAjaniJAKuzdzalJ, et al.Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med2021; 384: 1191–1203.
27.
JanjigianYYShitaraKMoehlerM, et al.First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet2021; 398: 27–40.
28.
BajorinDFWitjesJAGschwendJE, et al.Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med2021; 384: 2102–2114.
29.
ChoueiriTKPowlesTBurottoM, et al.Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med2021; 384: 829–841.
30.
SchmidPCortesJPusztaiL, et al.Pembrolizumab for early triple-negative breast cancer. N Engl J Med2020; 382: 810–821.
31.
SunJ-MShenLShahMA, et al.Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet2021; 398: 759–771.
32.
Keytruda (pembrolizumab) (prescribing information). Whitehouse Station, NJ: Merck & Co., Inc., July 2021, p. 101.
33.
Keytruda (pembrolizumab) (prescribing information). Whitehouse Station, NJ: Merck & Co., Inc., December 2021, p. 37.
34.
ChoueiriTKTomczakPParkSH, et al.Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N Engl J Med2021; 385: 683–694.
35.
JanjigianYYKawazoeAYañezP, et al.The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature2021; 600: 727–730.
36.
ColomboNDubotCLorussoD, et al.Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med2021; 385: 1856–1867.
37.
MotzerRAlekseevBRhaS-Y, et al.Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med2021; 384: 1289–1300.
38.
TagawaSTBalarAVPetrylakDP, et al.TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol2021; 39: 2474–2485.
39.
ShitaraKBangY-JIwasaS, et al.Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med2020; 382: 2419–2430.
40.
RiessJWGandaraDRFramptonGM, et al.Diverse EGFR exon 20 insertions and co-occurring molecular alterations identified by comprehensive genomic profiling of NSCLC. J Thorac Oncol2018; 13: 1560–1568.
41.
OxnardGRLoPCNishinoM, et al.Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol2013; 8: 179–184.
WuJ-YWuS-GYangC-H, et al.Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res2008; 14: 4877–4882.
44.
NaidooJSimaCSRodriguezK, et al.Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: clinical outcomes and response to erlotinib. Cancer2015; 121: 3212–3220.
45.
YangJCHSequistLVGeaterSL, et al.Clinical activity of Afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol2015; 16: 830–838.
46.
PiotrowskaZWangYSequistLV, et al.ECOG-ACRIN 5162: a phase II study of osimertinib 160 mg in NSCLC with EGFR exon 20 insertions.J Clin Oncol2020; 38: 9513–9513.
47.
van VeggelBMadeiraRSantosJFV, et al.Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer. Lung Cancer2020; 141: 9–13.
48.
KimTMOckC-YKimM, et al.Phase II study of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation: a multicenter trial of the Korean cancer study group (LU17-19). Ann Oncol2019; 30: v628.
49.
YangGLiJXuH, et al.EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: molecular heterogeneity and treatment outcome from nationwide real-world study. Lung Cancer2020; 145: 186–194.
50.
WangYYangGLiJ, et al.Real-world treatment outcome of advanced Chinese NSCLC EGFR exon 20 insertion patients.J Clin Oncol2019; 37: 9043–9043.
51.
ChoudhuryNJSchoenfeldAJFlynnJ, et al.Response to standard therapies and comprehensive genomic analysis for patients with lung adenocarcinoma with EGFR exon 20 insertions. Clin Cancer Res2021; 27: 2920–2927.
52.
MetroGBaglivoSBellezzaG, et al.Sensitivity to immune checkpoint blockade in advanced non-small cell lung cancer patients with EGFR exon 20 insertion mutations. Genes (Basel)2021; 12: 679.
SoumeraiTEDonoghueMTABandlamudiC, et al.Clinical utility of prospective molecular characterization in advanced endometrial cancer. Clin Cancer Res2018; 24: 5939–5947.
55.
OakninATinkerAVGilbertL, et al.Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair–deficient endometrial cancer. JAMA Oncol2020; 6: 1766–1772.
56.
KorcMFrieselR. The role of fibroblast growth factors in tumor growth. Curr Cancer Drug Targets2009; 9: 639–651.
57.
AraiYTotokiYHosodaF, et al.Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology2014; 59: 1427–1434.
58.
JavleMLoweryMShroffRT, et al.Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J Clin Oncol2018; 36: 276–282.
59.
Truseltiq (infigratinib) (prescribing information). Brisbane, CA: QED Therapeutics, Inc., 2021, p. 3.
60.
Pemazyre (pemigatinib) (prescribing information). Wilmington, DE: Incyte Corporation, 2021, p. 1.
61.
RielyGJNealJWCamidgeDR, et al.Activity and safety of mobocertinib (TAK-788) in previously treated non–small cell lung cancer with EGFR exon 20 insertion mutations from a phase I/II trial. Cancer Discov2021; 11: 1688–1699.
62.
ZhouCRamalingamSSKimTM, et al.Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion–positive metastatic non–small cell lung cancer: a phase 1/2 open-label nonrandomized clinical trial. JAMA Oncol2021; 7: e214761.
LiuYLiHZhuJ, et al.The prevalence and concurrent pathogenic mutations of KRASG12C in northeast Chinese non-small-cell lung cancer patients. Cancer Manag Res2021; 13: 2447–2454.
65.
AraujoLHSouzaBMLeiteLR, et al.Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer. BMC Cancer2021; 21: 193.
66.
HongDSFakihMGStricklerJH, et al.KRAS G12c inhibition with sotorasib in advanced solid tumors. N Engl J Med2020; 383: 1207–1217.
FalchookGSKurzrockRAminHM, et al.First-in-Man phase I trial of the selective MET inhibitor tepotinib in patients with advanced solid tumors. Clin Cancer Res2020; 26: 1237–1246.
69.
AwadMMOxnardGRJackmanDM, et al.MET Exon 14 mutations in non–small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-met overexpression. J Clin Oncol2016; 34: 721–730.
70.
ZhaoXChengCGouJ, et al.Expression of tissue factor in human cervical carcinoma tissue. Exp Ther Med2018; 16: 4075–4081.
71.
CriscitielloCMorgantiSCuriglianoG. Antibody–drug conjugates in solid tumors: a look into novel targets. J Hematol Oncol2021; 14: 20.
HartLLFerrarottoRAndricZG, et al.Myelopreservation with trilaciclib in patients receiving topotecan for small cell lung cancer: results from a randomized, double-blind, placebo-controlled phase II study. Adv Ther2021; 38: 350–365.
77.
HusseinMMaglakelidzeMRichardsDA, et al.Myeloprotective effects of trilaciclib among patients with small cell lung cancer at increased risk of chemotherapy-induced myelosuppression: pooled results from three phase 2, randomized, double-blind, placebo-controlled studies. Cancer Manag Res2021; 13: 6207–6218.
78.
LiouSYStephensJMCarpiucKT, et al.Economic burden of haematological adverse effects in cancer patients. Clin Drug Investig2007; 27: 381–396.
79.
EpsteinRSAaproMSBasu RoyUK, et al.Patient burden and real-world management of chemotherapy-induced myelosuppression: results from an online survey of patients with solid tumors. Adv Ther2020; 37: 3606–3618.
80.
Harbeck N, Johnston S, Fasching P, et al. Abstract PD2-01: High Ki-67 as a biomarker for identifying patients with high risk early breast cancer treated in monarchE. Cancer Res 2021; 81 (4_Supplement): PD2-01.
81.
SorbyeHDragomirASundströmM, et al.High BRAF mutation frequency and marked survival differences in subgroups according to KRAS/BRAF mutation status and tumor tissue availability in a prospective population-based metastatic colorectal cancer cohort. PLoS One2015; 10: e0131046.
82.
BoscoeANRollandCKelleyRK. Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review. J Gastrointest Oncol2019; 10: 751–765.
83.
LeiMSiemersNOPandyaD, et al.Analyses of PD-L1 and inflammatory gene expression association with efficacy of nivolumab ± ipilimumab in gastric cancer/gastroesophageal junction cancer. Clin Cancer Res2021; 27: 3926–3935.
84.
SchmidPCortesJDentR, et al.Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med2022; 386: 556–567.
85.
GrobJ-JGonzalezRBasset-SeguinN, et al.Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase II trial (KEYNOTE-629). J Clin Oncol2020; 38: 2916–2925.
86.
MaubecEPetrowPScheer-SenyarichI, et al.Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol2011; 29: 3419–3426.
87.
NakamuraKOkuyamaRSaidaT, et al.Platinum and anthracycline therapy for advanced cutaneous squamous cell carcinoma. Int J Clin Oncol2013; 18: 506–509.
88.
LukeJJAsciertoPACarlinoMS, et al.KEYNOTE-716: phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. Futur Oncol2020; 16: 4429–4438.
89.
SienaSDi BartolomeoMRaghavK, et al.Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol2021; 22: 779–789.
90.
LiBTSmitEFGotoY, et al.Trastuzumab deruxtecan in HER2-mutant non–small-cell lung cancer. N Engl J Med2022; 386: 241–251.
91.
ModiSParkHMurthyRK, et al.Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low–expressing advanced breast cancer: results from a phase ib study. J Clin Oncol2020; 38: 1887–1896.
92.
YamaguchiKBangY-JIwasaS, et al.Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: results of the exploratory cohorts in the phase II, multicenter, open-label DESTINY-Gastric01 study. Ann Oncol 2020; 31: S841–S73.
93.
HechtJRBangY-JQinSK, et al.Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC—a randomized phase III trial. J Clin Oncol2016; 34: 443–451.
94.
Thuss-PatiencePCShahMAOhtsuA, et al.Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol2017; 18: 640–653.
95.
MakiyamaASukawaYKashiwadaT, et al.Randomized, phase II study of trastuzumab beyond progression in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: WJOG7112G (T-ACT study). J Clin Oncol2020; 38: 1919–1927.
96.
DavisAAPatelVG. The role of PD-L1 expression as a predictive biomarker: an analysis of all US food and drug administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer2019; 7: 278.
97.
HirschFRMcElhinnyAStanforthD, et al.PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol2017; 12: 208–222.
98.
TsaoMSKerrKMKockxM, et al.PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project. J Thorac Oncol2018; 13: 1302–1311.
99.
US Food and Drug Administration. Developing and labeling in vitro companion diagnostic devices for a specific group of oncology therapeutic products guidance for industry,https://www.fda.gov/media/120340/download (2020, accessed 27 May 2022).
